Ketamine Offers Promise to Veterans with PTSD
September 24th, 2021
App, Exclusive, Psychedelics, Top Story
Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue.
The FDA’s decision to approve Spravato, an esketamine nasal spray, to treat depression and suicidal ideations marked the beginning of a psychedelic revolution in mental healthcare. Researchers believe that ketamine could also play a role in treating other mental health conditions, including PTSD and its many symptoms.
Let’s take a look at ketamine’s promise in treating PTSD and how KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MY0) (“Ketamine One” or the “Company”) aims to bring treatments to veterans and other sufferers of mental health conditions.
Ketamine Shows Promise
Ketamine has shown the potential to treat PTSD in several clinical studies.
For example, a 2014 study found that intravenous ketamine was associated with significant and rapid reductions in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion. In addition, researchers reported that the treatment was generally well-tolerated without persistent dissociative symptoms.
More recently, a 2021 study conducted by Mount Sinai researchers found that repeated infusions with ketamine over two weeks significantly reduced symptom severity in many patients while also helping minimize depression symptoms. While improvement occurred after just 24 hours, the benefit was “significantly greater” at two weeks and lasted ~30 days.
Bringing Treatments to Veterans
Ketamine infusion centers are becoming increasingly common across North America.
For example, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) recently signed a non-binding letter of intent with Veteran Services USA to lease 5,000 sq. ft. of space over five years in Blue Island, Illinois, to provide ketamine-assisted therapies. Its goal is to create a first-of-its-kind healing experience for veterans who have PTSD.
“We are very proud to be part of an important project such as this with Veteran Services USA, which will allow KetamineOne to showcase its innovative approach to care and treatment by addressing veterans’ unique needs,” said Interim CEO Adam Deffett. “Our company sees an immediate need for its services and has a special opportunity to help.”
Part of a Broader Picture
Ketamine’s potential is just starting to be realized, and the Company plans to build a leading network of clinics.
There are more than 200 active clinical trials involving ketamine in the United States, according to ClinicalTrials.gov. Researchers are evaluating the breakthrough drug to treat conditions like epilepsy, bipolar depression, postpartum depression, perinatal depression, cognitive dysfunction, autism spectrum disorder, and countless other conditions.
In the meantime, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) aims to consolidate medical clinics and become a North American leader in mental health treatments. Currently, the Company has 16 clinics across North America and acquired a contract research organization (CRO) to expand into the clinical side of the industry.
Ketamine has shown tremendous potential for treating PTSD, but that’s just scratching the surface of what’s possible.
Ketamine One’s (NEO: MEDI) (OTC: KONEF) (FFT: MY0) acquisition of KGK Science, a CRO, brings 24 years of experience across pharmaceuticals, cannabis, and emerging psychedelics. In conjunction with its network of clinics, the company is well-positioned to become a leader in conducting cutting-edge clinical research in the space.
For more information, visit the Company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.